CYP19A1 and chronic obstructive pulmonary disease: On the other hand, recent evidence [14-17] also recommend the evaluation of other risk factors related to low mass and risk of fragility fracture and not considered in the FRAXTM tool when assessing fracture risk such as the presence of chronic obstructive pulmonary disease (COPD), the use of some drugs such as aromatase inhibitors (increasingly more frequent in women treated for breast cancer), daily calcium intake and usual physical activity which are related to bone mass and risk of fragility fracture.